Catalyst Event
CLOBOT Co Ltd (466100) · Trading Issue
From Akros SCHK HK-Korea Humanoid Robotics Index (ASHKHRB)
6/8/2026, 12:00:00 AM
Clobot Co Ltd (KOSDAQ: 466100) announced on 2026-04-03 a shareholder allotment rights offering with a public offering of forfeited shares to raise approximately KRW 200.0 billion, issuing 5,494,500 new common shares for operating funds and acquisition of other companies' securities. This is a qualifying corporate action because it changes share count and existing holders' rights.
Korean Translation
운영자금 및 M&A 자금 조달을 위한 약 2,000억원 규모의 주주배정 유상증자. 2026년 4월 3일 공시되었으며, 권리락일은 2026년 6월 9일임.
Related Recent Events
Neuromeka Co Ltd (348340) · Trading Issue
Confirmed bonus issue of 0.5 shares per existing share, with an ex-rights date of 2026-07-31. A price impact of ≥10% is estimated as it is a significant corporate action, scheduled.
7/31/2026, 12:00:00 AM
Neuromeka Co Ltd (348340) · Trading Issue
Confirmed rights offering with an ex-rights date of 2026-06-12. The offering aims to raise ~150B KRW, increasing the share count by ~24%. A price impact of ≥10% is estimated due to significant share dilution, scheduled.
6/12/2026, 12:00:00 AM
Johnson Electric Holdings Ltd (179) · Earnings Release
Full-year financial results for the year ended March 31, 2026, and consideration of a final dividend on May 28, 2026, with medium importance estimated as annual results typically impact price by at least 5%, scheduled.
5/28/2026, 12:00:00 AM
AAC Technologies Holdings Inc (2018) · Other
Ex-dividend date for the proposed 2025 final dividend of HK$0.35 per share is scheduled for May 26, 2026. Low importance estimated as ex-dividend dates usually result in price adjustments ≥1% scheduled.
5/26/2026, 12:00:00 AM
Neuromeka Co Ltd (348340) · Earnings Release
Q1 2026 earnings release on 2026-05-22. A price impact of ≥5% is estimated based on the company's recent history of operating losses, scheduled.
5/22/2026, 12:00:00 AM
AAC Technologies Holdings Inc (2018) · Other
Annual General Meeting scheduled for May 21, 2026 to approve 2025 financial results and the final dividend. Low importance estimated as routine meetings typically have ≥1% price impact scheduled.
5/21/2026, 12:00:00 AM